抗病毒联合疗法市场－全球产业规模、份额、趋势、机会和预测，按类型、药物组合、给药途径、配销通路、适应症、地区和竞争格局划分，2020-2030年预测

2024年全球抗病毒联合疗法市场规模为527.2亿美元，预计2030年将以6.85%的复合年增长率成长至784.6亿美元。抗病毒联合疗法是指同时使用多种抗病毒药物治疗病毒感染，旨在提高疗效、降低抗药性并更有效地抑制病毒复製。该市场的成长主要受全球范围内爱滋病、肝炎和流感等病毒感染病例不断增加以及抗药性病毒株的出现所驱动，这些因素都要求采用多药联合疗法。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球抗病毒联合疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（品牌药、非品牌药）
  • 依药物组合分类（DNA聚合酶抑制剂、逆转录酶抑制剂、蛋白酶抑制剂、神经氨酸酶抑制剂、其他）
  • 依给药途径（口服、静脉注射）
  • 按适应症（人类免疫缺乏病毒、肝炎、其他）
  • 按配销通路（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美抗病毒联合疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗病毒联合疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗病毒联合疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲抗病毒联合疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲抗病毒联合疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球抗病毒联合疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Celltrion Inc.
• GlaxoSmithKline plc
• Gilead Sciences, Inc
• AbbVie, Inc.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Cipla Limited
• Viatris Inc
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd

第十六章：策略建议

第17章调查会社について・免责事项

The Global Antiviral Combination Therapy Market, valued at USD 52.72 Billion in 2024, is projected to experience a CAGR of 6.85% to reach USD 78.46 Billion by 2030. Antiviral combination therapy involves the simultaneous administration of multiple antiviral drugs to treat viral infections, aiming to enhance efficacy, reduce drug resistance development, and achieve more potent viral suppression. The market's growth is primarily driven by the escalating global prevalence of viral infections such as HIV, hepatitis, and influenza, along with the increasing emergence of drug-resistant viral strains requiring multi-drug approaches.

Key Market Drivers

The Global Antiviral Combination Therapy Market is significantly influenced by the persistently rising prevalence of viral infections worldwide. The continuous emergence and spread of diverse viral pathogens necessitate advanced and often multi-drug treatment approaches to manage disease progression effectively and mitigate severe outcomes. For instance, according to the Pan American Health Organization / World Health Organization, in December 2023, the Region of the Americas alone reported over 4.2 million new cases of dengue fever, surpassing the previous record from 2019 by more than a million cases, as highlighted in their Situation Report N.1: Dengue Epidemiological Situation in the Americas. Such widespread outbreaks and increasing incidence rates across various viral diseases create an urgent and sustained demand for robust antiviral combination therapies that can address complex viral dynamics and patient needs.

Key Market Challenges

The high cost associated with developing novel combination therapies and their subsequent pricing presents a significant impediment to the growth of the Global Antiviral Combination Therapy Market. The substantial financial investment required for research and development directly translates into elevated drug prices, creating access barriers in numerous regions globally. This restricts patient access and limits the adoption of these advanced treatments, particularly in healthcare systems with budget constraints.

Key Market Trends

The application of Artificial Intelligence in drug discovery represents a significant trend in the global antiviral combination therapy market by accelerating the identification and optimization of novel therapeutic agents. AI algorithms are increasingly deployed to analyze complex biological data, predict drug efficacy, and streamline the screening of potential antiviral compounds, thereby reducing the time and cost associated with early-stage development. This technological integration is evidenced by the active engagement of international organizations, with the Council for International Organizations of Medical Sciences (CIOMS) holding meetings for its Working Group on Artificial Intelligence in Pharmacovigilance as recently as September 2025, signaling the industry's growing commitment to AI adoption across the pharmaceutical lifecycle.

Key Market Players

• Celltrion Inc.
• GlaxoSmithKline plc
• Gilead Sciences, Inc
• AbbVie, Inc.
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Cipla Limited
• Viatris Inc
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Antiviral Combination Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antiviral Combination Therapy Market, By Type:

• Branded
• Generic

Antiviral Combination Therapy Market, By Drug Combination:

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

Antiviral Combination Therapy Market, By Route of Administration:

• Oral
• Intravenous

Antiviral Combination Therapy Market, By Indication:

• Human Immunodeficiency Virus
• Hepatitis
• Others

Antiviral Combination Therapy Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Antiviral Combination Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antiviral Combination Therapy Market.

Available Customizations:

Global Antiviral Combination Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antiviral Combination Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Branded, Generic)
  • 5.2.2. By Drug Combination (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
  • 5.2.3. By Route of Administration (Oral, Intravenous)
  • 5.2.4. By Indication (Human Immunodeficiency Virus, Hepatitis, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Antiviral Combination Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Combination
  • 6.2.3. By Route of Administration
  • 6.2.4. By Indication
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antiviral Combination Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Combination
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Indication
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Antiviral Combination Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Combination
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Indication
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Antiviral Combination Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Combination
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Indication
      • 6.3.3.2.5. By Distribution Channel

7. Europe Antiviral Combination Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Combination
  • 7.2.3. By Route of Administration
  • 7.2.4. By Indication
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antiviral Combination Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Combination
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Indication
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Antiviral Combination Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Combination
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Indication
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Antiviral Combination Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Combination
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Indication
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Antiviral Combination Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Combination
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Indication
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Antiviral Combination Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Combination
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Indication
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Antiviral Combination Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Combination
  • 8.2.3. By Route of Administration
  • 8.2.4. By Indication
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antiviral Combination Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Combination
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Indication
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Antiviral Combination Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Combination
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Indication
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Antiviral Combination Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Combination
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Indication
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Antiviral Combination Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Combination
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Indication
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Antiviral Combination Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Combination
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Indication
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Antiviral Combination Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Combination
  • 9.2.3. By Route of Administration
  • 9.2.4. By Indication
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antiviral Combination Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Combination
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Indication
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Antiviral Combination Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Combination
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Indication
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Antiviral Combination Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Combination
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Indication
      • 9.3.3.2.5. By Distribution Channel

10. South America Antiviral Combination Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Combination
  • 10.2.3. By Route of Administration
  • 10.2.4. By Indication
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antiviral Combination Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Combination
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Indication
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Antiviral Combination Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Combination
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Indication
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Antiviral Combination Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Combination
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Indication
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antiviral Combination Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Celltrion Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline plc
• 15.3. Gilead Sciences, Inc
• 15.4. AbbVie, Inc.
• 15.5. Bristol-Myers Squibb Company
• 15.6. Janssen Pharmaceuticals, Inc.
• 15.7. Cipla Limited
• 15.8. Viatris Inc
• 15.9. Merck & Co., Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer